Designation: B.S. Pharm; Ph.D., Technical Consultant for Formulation and Manufacturing
Dr. David Beach has 30+ years of experience working in the pharmaceutical industry and Heath Sciences area. He is the former President and CEO of TorPharm, the U.S. division of Apotex, Inc. He grew this company from a ‘greenfield start-up’ to over $400 million in revenue and 1,000+ employees during his decade long tenure as President.
Dr. Beach was also a senior scientist with DuPont Pharmaceuticals and a key participant in the design and qualification of a new pharmaceutical research facility in Wilmington, DE. He managed a new product development group and was also responsible for the preparation of clinical supplies for Phase 1 through Phase III clinical studies of DuPont’s new chemical entity program during this time. During his tenure at DuPont he was a co-inventor on two U.S. patents in the area of polymer mediated sustained release technology. Prior to joining the Apotex Group, Dr. Beach held a number of progressive positions with SuperPharm Corporation, a Division of Goldline Laboratories, and Schering-Plough in both veterinary and human health divisions. Dr. Beach is regularly sought by investors, academics and media for advice and insights on global trends and issues in pharmaceutical operations and policy.
Dr. Beach holds a BS in Pharmacy from Union University, Alban College of Pharmacy and a PhD in pharmaceutics from the University of Maryland at Baltimore, specializing in physical pharmacy and dosage form development.